Welcome to the healthcare professionals section
In this section, you will find information on DualVis™ and its use in knee osteoarthritis (OA).
We have included DualVis™ prescribing information, clinical references, a video demonstrating the mechanism of action of DualVis™ and other useful information.
If you require further assistance, please contact us.
A clinical study was conducted studying the effects of DualVis™ versus a high molecular weight Hyaluronic Acid (HA), a low molecular weight HA and placebo. This double blind, placebo controlled, study in Canada showed that patients administered with DualVis™ had fewer pain scores when walking and at rest compared to the other three arms in the study, notably in a shorter period of time.
DualVis patients had the lowest pain score after the 2nd injection and this was maintained for up to 16 weeks.
An innovative product for knee osteoarthritis, DualVis™ is the only product on the market that contains 2 Hyaluronic Acids in 1 syringe for a sequential injection.
Chamber 1 contains: Low molecular weight Hyaluronic Acid (HA) – High concentration
Chamber 2 contains: High molecular weight Hyaluronic Acid (HA) – Low concentration
DualVis™ offers both patients and doctors the DMC concept: Dual Molecular weight and Concentration concept in a single syringe.
All viscosupplementation products try to help knee osteoarthritis patients to regain a healthy physiological state of the knee. Low molecular weight Hyaluronic Acid (HA) is known to be able to act as a lubricant in the knee whereas high molecular Hyaluronic Acid (HA) is known for its ability to absorb shocks experienced by the knee.
Low molecular weight Hyaluronic Acid (HA) has 2 other functions:
It diffuses through the cartilage to protect the chondrocytes (note: a molecule which helps create endogenous HA and proteoglycans) which are commonly destroyed in knee OA patients. This is often termed as the CAGING EFFECT.
It diffuses to the synoviocytes at the synovial membrane to activate them. This results in the generation of endogenous HA. This action is known as the MECHANOSENSITIVE EFFECT.
This is why DualVis™ has a concentration of low molecular weight Hyaluronic Acid (HA) – to achieve these 3 criteria needed in an OA knee.
The high molecular weight Hyaluronic Acid (HA) is at a lower concentration as it only has 1 function (shock absorber) and it only has to maintain this function while the low molecular weight HA is active.
DualVis™ can be re-administered to patients after 6 months.
DualVis™ is administered via an intra-articular injection into the knee synovial capsule. Care should always be taken to ensure that entry into the synovial capsule is obtained. There are various techniques to do an intra-articular injection. Administration depends greatly on what you are most comfortable with.
There were no serious adverse events during the clinical study. Non-serious adverse events included pain and local swelling at the injection site (21%), erythema at the injection site (12%), and stiffness in the index knee (7%) amongst all groups.